Quick Answer
Propanc Biopharma, Inc. reported R&D Expense of $223.7 thousand for fiscal year 2025.
Propanc Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $223.7K | -9.8% |
| 2024 | $248.1K | +0.1% |
| 2023 | $247.9K | -3.2% |
| 2022 | $256.1K | +10.9% |
| 2021 | $231.0K | +28.3% |
| 2020 | $180.0K | -30.9% |
| 2019 | $260.3K | -85.7% |
| 2018 | $1.83M | +87.9% |
| 2017 | $971.8K | -32.8% |
| 2016 | $1.45M | +977.2% |
| 2015 | $134.3K | +1544.5% |
| 2014 | $8.2K | -33.8% |
| 2013 | $12.3K | +133.8% |
| 2012 | $5.3K | -98.6% |
| 2011 | $385.8K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $20.0K | -63.3% | -66.8% |
| September 30, 2025 | $60.2K | -2.5% | +11.3% |
| March 31, 2025 | $54.1K | -17.3% | -0.5% |
| December 31, 2024 | $54.4K | -52.3% | -11.9% |
| September 30, 2024 | $61.7K | +280.0% | -5.7% |
| March 31, 2024 | $65.4K | -0.9% | -42.6% |
| December 31, 2023 | $114.0K | +52.3% | +602.0% |
| September 30, 2023 | $16.2K | -84.0% | -75.4% |
- Propanc Biopharma, Inc. showed a decrease of -9.8% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Propanc Biopharma, Inc.’s r&d expense has declined by 42.0% (from $385.8 thousand to $223.7 thousand).
- The most recent figure is from Propanc Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: